Forcefield Therapeutics

📍 London, United Kingdom👥 8 employees💰 Last funded Nov 2020
Biotechnology Research🌐 forcefieldtx.com
Website LinkedIn
Forcefield Therapeutics is a pioneer of best-in-class therapeutics to retain heart function via the protection of cardiomyocytes. Forcefield Tx was founded on the work of Professor Mauro Giacca, an authority in cardiovascular disease and genetic biology and the Heat of the School of Cardiovascular Medicine and Sciences at King’s College London as well as industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI). Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by a leading FTSE 250 healthcare company, Syncona.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Forcefield Therapeutics?
Forcefield Therapeutics has 1 investors on record on gritt.io.
When did Forcefield Therapeutics last raise funding?
The most recent investment in Forcefield Therapeutics recorded on gritt.io was in November 2020.
What industry is Forcefield Therapeutics in?
Forcefield Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Forcefield Therapeutics based?
Forcefield Therapeutics is headquartered in London, United Kingdom.